Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest

Drug Safety

Volumn 37, Issue 8, 2014, Pages 557-567

  Boyce, Richard D ^a   Ryan, Patrick B ^b   Norén, G Niklas ^c   Schuemie, Martijn J ^b   Reich, Christian ^d   Duke, Jon ^e   Tatonetti, Nicholas P ^f   Trifirò, Gianluca ^g,h   Harpaz, Rave ⁱ   Overhage, J Marc ^j   Hartzema, Abraham G ^k   Khayter, Mark ^l   Voss, Erica A ^b   Lambert, Christophe G ^m   Huser, Vojtech ⁿ   Dumontier, Michel ⁱ  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c UPPSALA MONITORING CENTRE   (Sweden)

^d ASTRAZENECA   (United Kingdom)

^e REGENSTRIEF INSTITUTE   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g UNIVERSITY OF MESSINA   (Italy)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ STANFORD UNIVERSITY   (United States)

^j SIEMENS CORPORATE RESEARCH   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l Ephir   (United States)

^m MONTANA STATE UNIVERSITY   (United States)

ⁿ NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INFORMATION; DRUG SAFETY; INFORMATION SCIENCE; KNOWLEDGE BASE; NOTE; PRIORITY JOURNAL; STANDARDIZATION; DRUG DATABASE; EVIDENCE BASED MEDICINE; HUMAN; STANDARD; STANDARDS;

DATABASES, PHARMACEUTICAL; EVIDENCE-BASED MEDICINE; HUMANS; REFERENCE STANDARDS;

EID: 84906313665     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0189-0     Document Type: Note

References (46)

1. Bush V. As we may think. The Atlantic. July 1945.
2. Yu AC. Methods in biomedical ontology. J Biomed Inform. 2006;39(3):252-66. doi:10.1016/j.jbi.2005.11.006.
3. Marshall MS, Boyce R, Deus HF, Zhao J, Willighagen EL, Samwald M, et al. Emerging practices for mapping and linking life sciences data using RDF - a case series. Web Semant Sci Serv Agents World Wide Web. 2012;14:2-13.
4. Jacunski A, Tatonetti NP. Connecting the dots: applications of network medicine in pharmacology and disease. Clin Pharmacol Therap. 2013;94(6):659-69. doi:10.1038/clpt.2013.168.
5. Yeleswarapu S, Rao A, Joseph T, Saipradeep VG, Srinivasan R. A pipeline to extract drug-adverse event pairs from multiple data sources. BMC Med Inform Decis Mak. 2014;14(1):13.
6. DuMouchel W, Ryan PB, Schuemie MJ, Madigan D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf. 2013;36(Suppl 1):S123-32. doi:10.1007/s40264-013-0106-y.
7. Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S73-82. doi:10.1007/s40264-013-0105-z.
8. Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401-15. doi:10.1002/sim.5620.
9. Ryan PB, Schuemie MJ. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 2013;36(Suppl 1):S171-80. doi:10.1007/s40264-013-0110-2.
10. Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S59-72. doi:10.1007/s40264-013-0099-6.
11. Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S95-106. doi:10.1007/s40264-013- 0101-3.
12. Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(Suppl 1):S143-58. doi:10.1007/s40264- 013-0108-9.
13. Schuemie MJ, Madigan D, Ryan PB. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S133-42. doi:10.1007/s40264-013-0107-x.
14. Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S83-93. doi:10.1007/s40264-013-0100-4.
15. Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifiro G, Matthews JN, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50(10):890-7.
16. Schuemie MJ, Gini R, Coloma PM, Straatman H, Herings RM, Pedersen L, et al. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Saf. 2013;36(Suppl 1):S159-69. doi:10.1007/s40264-013-0109-8.
17. Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in eudravigilance postauthorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 2010;33(6):475-87. doi:10.2165/11534410-000000000-00000.
18. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31 doi:10.1126/scitranslmed.3003377.
19. Hochberg AM, Hauben M, Pearson RK, O'Hara DJ, Reisinger SJ, Goldsmith DI, et al. An evaluation of three signal-detection algorithms using a highly inclusive reference event database. Drug Saf. 2009;32(6):509-25. doi:10.2165/00002018-200932060-00007.
20. Norén GN, Bergvall T, Ryan PB, Juhlin K, Schuemie MJ, Madigan D. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S107-21. doi:10.1007/s40264-013- 0095-x.
21. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33-47. doi:10.1007/s40264-013-0097-8.
22. Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36(1):13-23. doi:10.1007/s40264-012-0002-x.
23. Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18(4):441-8. doi:10.1136/amiajnl-2011-000116.
24. Lee D, de Keizer N, Lau F, Cornet R. Literature review of SNOMED CT use. JAMIA. 2014;21(e1):e11-9. doi:10.1136/amiajnl-2013-001636.
25. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54-60. doi:10.1136/amiajnl-2011-000376.
26. Defalco FJ, Ryan PB, Soledad Cepeda M. Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Methodol. 2013;13(1):58-67. doi:10.1007/s10742-012-0102-1.
27. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(1):D1091-7. doi:10.1093/nar/gkt1068.
28. Schriml LM, Arze C, Nadendla S, Chang YW, Mazaitis M, Felix V, et al. Disease ontology: a backbone for disease semantic integration. Nucleic Acids Res. 2012;40(Database issue):D940-6. doi:10.1093/nar/gkr972.
29. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials. gov results database - update and key issues. N Engl J Med. 2011;364(9):852-60. doi:10.1056/NEJMsa1012065.
30. Duke J, Friedlin J, Ryan P. A quantitative analysis of adverse events and "overwarning" in drug labeling. Arch Intern Med. 2011;171(10):944-6. doi:10.1001/archinternmed.2011.182.
31. Duke JD, Friedlin J. ADESSA: a real-time decision support service for delivery of semantically coded adverse drug event data. AMIA Annu Symp Proc. 2010;2010:177-81.
32. Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21-37.
33. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Therap. 1977;21(3):247-54. (Pubitemid 8064243)
34. Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L. Adverse drug reactions - a matter of opinion. Clin Pharmacol Therap. 1976;19(5 Pt 1):489-92.
35. Koh Y, Li SC. A new algorithm to identify the causality of adverse drug reactions. Drug Saf. 2005;28(12):1159-61. (Pubitemid 41776006)
36. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug-reactions. Clin Pharmacol Therap. 1981;30(2):239-45. (Pubitemid 12149145)
37. Koh Y, Yap CW, Li SC. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system. Int J Med Inform. 2008;77(6):421-30. doi:10.1016/j.ijmedinf.2007.08. 010. (Pubitemid 351626709)
38. Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Therap. 1995;58(6):692-8. doi:10.1016/0009-9236(95)90026-8. (Pubitemid 26018854)
39. Duke JD, Han X, Wang ZP, Subhadarshini A, Karnik SD, Li XC et al. Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. Plos Comput Biol. 2012;8(8):e1002614. doi:10.1371/journal.pcbi.1002614.
40. Cami A, Arnold A, Manzi S, Reis B. Predicting adverse drug events using pharmacological network models. Sci Transl Med. 2011;3(114):114ra127. doi:10.1126/scitranslmed.3002774.
41. Cami A, Manzi S, Arnold A, Reis BY. Pharmacointeraction network models predict unknown drug-drug interactions. Plos One. 2013;8(4):e61468. doi:10.1371/journal.pone.0061468.
42. Cheng FX, Li WH, Wang XC, Zhou YD, Wu ZR, Shen J, et al. Adverse drug events: database construction and in silico prediction. J Chem Inf Model. 2013;53(4):744-52. doi:10.1021/Ci4000079.
43. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Therap. 2012;91(6):1010-21. doi:10.1038/clpt.2012.50.
44. Juhlin K, Ye X, Star K, Norén GN. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy. Pharmacoepidemiol Drug Saf. 2013;22(10):1119-29. doi:10.002/pds.3474.
45. Karimi G, Star K, Norén GN, Hagg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One. 2013;8(7):e68938. doi:10.1371/journal.pone.0068938.
46. Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf. 2013;22(3):294-301. doi:10.1002/pds.3351.